By Fineline Cube Bio-sincerity (SHE: 301096) announced that China’s National Medical Products Administration (NMPA) has approved its investigational drug BIOS0629-109 for clinical trials targeting advanced malignant tumors. The novel XPO1 inhibitor, developed through an exclusive licensing partnership with Zhongshen Innovation, represents a significant advancement in the company’s oncology pipeline and is registered under the Class 1 chemical drugs regulatory category.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA) |
| Approval Type | Clinical Trial Application Approval |
| Product | BIOS0629-109 – novel XPO1 inhibitor |
| Indication | Advanced malignant tumors |
| Approval Date | 2 July 2026 |
| Regulatory Classification | Class 1 innovative chemical drug |
Strategic Partnership Framework
| Partner | Responsibilities | Territory |
|---|---|---|
| Bio-sincerity | Research & development, clinical trials, regulatory registration filings | Greater China + International markets |
| Zhongshen Innovation | R&D translation, post-marketing manufacturing, sales, market expansion | Greater China only (Mainland China, Hong Kong, Macau, Taiwan) |
| Commercial Terms | Bio-sincerity to receive 10% royalty on Greater China sales revenue upon commercial launch | Greater China |
| International Rights | Retained exclusively by Bio-sincerity | Outside Greater China |
Drug Profile & Development Strategy
- Molecule: BIOS0629-109 – novel XPO1 inhibitor
- Therapeutic Area: Advanced malignant tumors
- Development Status: Phase I clinical trial initiation following NMPA approval
- Innovation Classification: Class 1 innovative drug (first-in-class or best-in-class designation)
- Partnership Structure: Exclusive licensing agreement established in November 2025
- Joint Development: Collaborative effort between Bio-sincerity and Zhongshen Innovation
Market Opportunity & Competitive Landscape
| Aspect | Details |
|---|---|
| Target Population | Patients with advanced malignant tumors requiring novel therapeutic approaches |
| XPO1 Inhibitor Market | Emerging class of targeted cancer therapeutics with demonstrated clinical potential |
| China Oncology Pipeline | High unmet need for innovative cancer treatments with domestic development capabilities |
| Commercial Potential | Dual revenue stream from direct international sales and Greater China royalties |
| Strategic Advantage | Leveraging Zhongshen Innovation’s commercial infrastructure while maintaining global rights |
Forward Outlook
The NMPA clinical trial approval positions Bio-sincerity to advance a promising oncology candidate through the Chinese regulatory pathway while maintaining full control over international markets. The strategic partnership with Zhongshen Innovation provides access to established commercial capabilities in Greater China without diluting Bio-sincerity’s global commercial potential.
Upon successful clinical development and regulatory approval, BIOS0629-109 could address significant unmet needs in the treatment of advanced malignancies. The 10% royalty structure ensures Bio-sincerity benefits from Greater China market success while focusing resources on global development and commercialization efforts.
This milestone reinforces Bio-sincerity’s commitment to innovative oncology drug discovery and demonstrates the viability of strategic partnerships to accelerate development timelines while optimizing commercial returns across different geographic markets.
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory approvals, partnership arrangements, and commercial expectations for BIOS0629-109. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market acceptance.-Fineline Info & Tech